The article deals with the use of biotechnological drugs (BTLG) in the treatment of children of the Republic of Belarus, mainly suffering from rheumatoid arthritis. This group of drugs is a new, very promising and insufficiently studied group in the world pediatric practice. The work assessed the effectiveness of the use of BTLG, taking into account the indications in pediatric practice.The results of studying the structure of patients receiving BTLG depending on the nosological unit of the disease, age, sex, place of residence of patients are presented; analyzes the effectiveness of de-escalation of therapy, switching to another drug, «escape» of the effect when using BTLG. The authors substantiate the need for a further differentiated approach to the use of the BTLG group in the treatment of severe forms of rheumatoid arthritis in children, the need to take into account the effects of the therapy.
- Литературы
- 1. Rizzuto, M. A. et al. Are nanotechnological approaches the future of treating inflammatory diseases? // Nanomedicine (Lond). – 2019. – Vol. 14, № 9. – P. 2379–2390. – doi: 10.2217/nnm-2019-0159. Epub 2019 Aug 15.
- 2. Garcia-Fernandez, A. et al. Evolution of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis // Arthritis Rheumatol. – 2020. – Vol. 72 (suppl. 10).
- 3. Halyiabar, Olha et al. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature // Pediatr. Drugs. – 2019. – Vol. 21, № 6. – P. 469–492. – doi: 10.1007/s40272-019-00362–6.
- 4. Klein, A. et al. Biologic Therapies in Polyarticulat Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry // ACR Open Rheumatol. – 2020. – Vol. 2, № 1. – P. 37–47. – doi: 10.1002/acr2.11091. Epub 2019 Nov 24.
- 5. Reynolds et al. When is switching warranted among biologic therapies in rheumatoid arthritis? – Expert. Rev. Pharmacoecon Outcomes Res. – 2012. – Vol. 3, № 12. – Р. 319–33. – doi: 10.1586/erp.12.27.
- 6. Shankar, G. et al. The quintessence of immunogenicity reporting for biotherapeutics // Nat. Biotechnol. – 2015. – Vol. 33, № 4. – P. 334–336. – doi: 10.1038/nbt.3181.
- References
- 1. Rizzuto, M. A. et al. Are nanotechnological approaches the future of treating inflammatory diseases? // Nanomedicine (Lond). – 2019. – Vol. 14, № 9. – P. 2379–2390. – doi: 10.2217/nnm-2019-0159. Epub 2019 Aug 15.
- 2. Garcia-Fernandez, A. et al. Evolution of Flare Rate and Tapering Strategies in Juvenile Idiopathic Arthritis.-Arthritis Rheumatol. – 2020. – Vol. 72 (suppl. 10).
- 3. Halyiabar, Olha et al. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature // Pediatr. Drugs. – 2019. – Vol. 21, № 6. – P. 469–492. – doi: 10.1007/s40272-019-00362-6.
- 4. Klein, A. et al. Biologic Therapies in Polyarticulat Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry // ACR Open Rheumatol. – 2020. – Vol. 2, № 1. – P. 37–47. – doi: 10.1002/acr2.11091. Epub 2019 Nov 24.
- 5. Reynolds et al. When is switching warranted among biologic therapies in rheumatoid arthritis? // Expert. Rev. Pharmacoecon Outcomes Res. – 2012. – Vol. 3, № 12. – P. 319–33. – doi: 10.1586/erp.12.27.
- 6. Shankar, G. et al. The quintessence of immunogenicity reporting for biotherapeutics // Nat. Biotechnol. – 2015. – Vol. 33, № 4. – P. 334–336. – doi: 10.1038/nbt.3181.
- Поступила 29.11.2021 г.